Major features of the 2021 WHO Classification of Tumors of the Central Nervous System: clinician’s view
https://doi.org/10.18705/2782-3806-2022-2-4-77-90
Abstract
Advances in the understanding of the molecular biology of central nervous system (CNS) tumors have prompted a new WHO classification of brain and spinal cord tumors in 2021 and integration it in routine clinical practice. Nowadays accurate diagnosis verification consists not only of the histological tumor type, but also includes its molecular-genetic characteristics. Differences in the genetic features of a tumor, even within the same histological type, will determine differences in the prognosis of the disease, and in the tactics of anticancer therapy. The introduced changes necessitate a comprehensive diagnosis of CNS tumors, thereby placing the responsibility for formulating the final diagnosis not only on pathologists. New approaches to classification make it possible to personalize anticancer treatment, as well as including new methods of targeted and immunotherapy, which today seems to be a key aspect of improving the survival of this category of patients.
About the Authors
Y. V. Dinikina
Almazov National Medical Research Centre, Saint Petersburg
Russian Federation
Russian Federation
Dinikina Yulia V., PhD, Head Department of pediatric oncohematology and BMT of Almazov National Medical Research Center; Head of the Laboratory of Pediatric Neuro-Immuno-Oncology of the Pesonalized Medicine Centre, Almazov National Medical Research Centrе
Akkuratova str., 2, Saint Petersburg, 197341
M. B. Belogurova
Almazov National Medical Research Centre, Saint Petersburg
Russian Federation
Russian Federation
Belogurova Margarita B., Dr. of Sci. (Med.), Professor, Leading Scientific Collaborator of Research Institute of Oncology and Hematology
Saint Petersburg
References
1. Ostrom QT, Gittleman H, Liao P, VecchioneKoval T, Wolinsky Y, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014. Neuro-Oncology, 2017; 19(S5): 1–88. DOI: 10.1093/neuonc/nox158.
2. Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW. The 2016 WHO classification of tumours of the central nervous system: a summary. Acta Neuropathol, 2016; 97–109. DOI: 10.1007/s00401-016-1545-1.
3. Хачатрян В.А., Ким А.В., Самочерных К.А., Гогорян С.Ф., Малхасян Ж.Г., Рабандияров М.Р., Голубова О.В., Сахно Л.В., Нестерова Л.П., Лебедев К.Э., Симонян Д.А. Злокачественные опухоли головного мозга у детей, сочетающиеся с гидроцефалией. Нейрохирургия и неврология Казахстана. 2009; 4(17): 1–7.
4. Базархандаева Т.Б., Хачатрян В.А., Самочерных К.А., Ким А.В., Забродская Ю.М., Дон О.А. Некоторые аспекты диагностики, морфологии и хирургического лечения опухолей задних отделов III желудочка и среднего мозга у детей (обзор литературы). Нейрохирургия и неврология детского возраста. 2013; 4(38): 71–84.
5. Ferguson S, Lesniak MS. Percival Bailey and the classification of brain tumors. Neurosurg Focus, 2005; 18(4): 1–6. DOI: 10.3171/foc.2005.18.4.8.
6. Louis DN, Perry A, Wesseling P, Brat DJ, Cree IA, Figarella-Branger D, Hawkins C, Ng HK, Pfister SM, Reifenberger G, Soffietti R, von Deimling A, Ellison DW. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. Neuro-Oncology, 2021; 23(8): 1231–1251. DOI: 10.1093/neuonc/noab106.
7. Bruford EA, Braschi B, Denny P, Jones TEM, Seal RL, Tweedie S. Guidelines for human gene nomenclature. Nature genetics. 2020; 52(8):754–758.
8. den Dunnen JT, Dalgleish R, Maglott DR, Hart KH, Greenblatt MS, McGowan-Jordan J, Roux AF, Smith T, Antonarakis SE, Taschner PEM. HGVS recommendations for the description of sequence variants: 2016 update. Hum Mutat. 2016; 37(6):564–569. DOI: 10.1002/humu.22981.
9. Louis DN, Wesseling P, Aldape K, Brat DJ, Capper D, Cree IA, Eberhart C, Figarella-Branger D, Fouladi M, Fuller GN, Giannini C, Haberler C, Hawkins C, Komori T, Kros JM, Ng HK, Orr BA, Park SH, Paulus W, Perry A, Pietsch, Reifenberger G, Rosenblum, Rous B, Sahm F, Sarkar C, Solomon DA, Tabori U, van den Bent MJ, von Deimling A, Weller M, White VA, Ellison DW. cIMPACTNOW update 6: new entity and diagnostic principle recommendations of the cIMPACTUtrecht meeting on future CNS tumor classification and grading. Brain Pathol. 2020; 30(4):844–856. DOI: 10.1111/bpa.12832.
10. Louis DN, Perry A, Burger P, Ellison DW, Reifenberger G, von Deimling A, Aldape K, Brat D, Collins VP, Eberhart C, Figarella-Branger D, Fuller GN, Giangaspero F, Giannini C, Hawkins C, Kleihues P, Korshunov A, Kros JM, Lopes MB, Ng HK, Ohgaki H, Paulus W, Pietsch T, Rosenblum M, Rushing E, Soylemezoglu F, Wiestler O, Wesseling P. International Society of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol. 2014; 24(5):429–435. DOI: 10.1111/bpa.12171.
11. Priesterbach-Ackley LP, Boldt HB, Petersen JK, Bervoets N, Scheie D, Ulhøi BP, Gardberg M, Brännström T, Torp SH, Aronica E, Küsters B, den Dunnen WFA, de Vos FYFL, Wesseling P, de Leng WWJ, Kristensen BW. Brain tumour diagnostics using a DNA methylation-based classifier as a diagnostic support tool. Neuropathol Appl Neurobiol. 2020; 46(5):478–492. DOI: 10.1111/nan.12610.
12. Ellison DW, Aldape KD, Capper D, Fouladi M, Gilbert MR, Gilbertson RJ, Hawkins C, Merchant TE, Pajtler K, Venneti S, Louis DN. cIMPACT-NOW update 7: advancing the molecular classification of ependymal tumors. Brain Pathol. 2020; 30(5):863–866. DOI: 10.1111/bpa.12866.
13. Mynarek M, von Hoff K, Pietsch T, Ottensmeier H, Warmuth-Metz M, Bison B, Pfister S, Korshunov A, Sharma T, Jaeger N, Ryzhova M, Zheludkova O, Golanov A, Rushing EJ, Hasselblatt M, Koch A, Schüller U, von Deimling A, Sahm F, Sill M, Rieenschneider MJ, Dohmen H, Monoranu CM, Sommer C, Staszewski O, Mawrin C, Schittenhelm J, Brück W, Filipski K, Hartmann C, Meinhardt M, Pietschmann K, Haberler C, Slavc I, Gerber NU, Grotzer M, Benesch M, Schlegel PG, Deinlein F, von Bueren AO, Friedrich C, Juhnke BO, Obrecht D, Fleischhack G, Kwiecien R, Faldum A, Kortmann RD, Kool M, Rutkowski S. Nonmetastatic medulloblastoma of early childhood: results from the prospective clinical trial HIT2000 and an extended validation cohort. J Clin Oncol. 2020; 38(18):2028–2040. DOI: 10.1200/JCO.19.03057.
14. Robinson GW, Gajjar A. Genomics paves the way for better infant medulloblastoma therapy. J Clin Oncol. 2020; 38(18):2010–2013. DOI: 10.1200/JCO.20.00593.
15. Pfaff E, Aichmüller C, Sill M, Stichel D, Snuderl M, Karajannis MA, Schuhmann MU, Schittenhelm J, Hasselblatt M, Thomas C, Korshunov A, Rhizova M, Wittmann A, Kaufhold A, Iskar M, Ketteler P, Lohmann D, Orr BA, Ellison DW, von Hoff K, Mynarek M, Rutkowski S, Sahm F, von Deimling A, Lichter P, Kool M, Zapatka M, Pfister SM, Jones DTW. Molecular subgrouping of primary pineal parenchymal tumors reveals distinct subtypes correlated with clinical parameters and genetic alterations. Acta Neuropathol. 2020; 139(2):243–257. DOI: 10.1007/s00401-019-02101-0.
16. Li BK, Vasiljevic A, Dufour C, Yao F, Ho BLB, Lu M, Hwang EI, Gururangan S, Hansford JR, Fouladi M, Nobusawa S, Laquerriere A, Delisle MB, Fangusaro J, Forest F, Toledano H, Solano-Paez P, Leary S, Birks D, Hoffman LM, Szathmari A, Faure-Conter C, Fan X, Catchpoole D, Zhou L, Schultz KAP, Ichimura K, Gauchotte G, Jabado N, Jones C, Loussouarn D, Mokhtari K, Rousseau A, Ziegler DS, Tanaka S, Pomeroy SL, Gajjar A, Ramaswamy V, Hawkins C, Grundy RG, Hill DA, Bouffet E, Huang A, Jouvet A. Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: Rare Brain Tumor Consortium registry study. Acta Neuropathol. 2020; 139(2):223–241. DOI: 10.1007/s00401-019-0211-y.
17. Sahm F, Schrimpf D, Olar A, Reuss D, Bissel J, Kratz A, Capper D, Schefzyk S, Hielscher T, Wang Q, Sulman EP, Adeberg S, Koch A, Okuducu AF, Brehmer S, Schittenhelm J, Becker A, Brokinkel B, Schmidt M, Ull T, Gousias K, Friederike A, Kessler, Lamszus K, Debus J, Mawrin C, Kim YJ, Simon M, Ketter R, Paulus W, Aldape KD, Herold-Mende C, von Deimling A. TERT promoter mutations and risk of recurrence in meningioma. J Natl Cancer Inst. 2016; 108(5):1–4. DOI: 10.1093/jnci/djv377.
18. Sievers P, Hielscher T, Schrimpf D, Stichel D, Reuss DE, Berghoff AS, Neidert MC, Wirsching HG, Mawrin C, Ketter R, Paulus W, Reifenberger G, Lamszus K, Westphal M, Etminan N, Ratliff M, Herold-Mende C, Pfister SM, Jones DTW, Weller M, Harter PN, Wick W, Preusser M, von Deimling A, Sahm F. CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. Acta Neuropathol. 2020; 140(3):409– 413. DOI: 10.1007/s00401-020-02188-w.
19. Gauchotte G, Peyre M, Pouget C, Cazals-Hatem D, Polivka M, Rech F, Varlet P, Loiseau H, Lacomme S, Mokhtari K, Kalamarides M, Bielle F. Prognostic value of histopathological features and loss of H3K27me3 immunolabeling in anaplastic meningioma: a multicenter retrospective study. J Neuropathol Exp Neurol. 2020;79(7):754–762. DOI: 10.1093/jnen/nlaa038.
20. Nassiri F, Mamatjan Y, Suppiah S, Badhiwala JH, Mansouri S, Karimi S, Saarela O, Poisson L, GepfnerTuma I, Schittenhelm J, Ng HK, Noushmehr H, Harter P, Baumgarten P, Weller M, Preusser M, Herold-Mende C, Tatagiba M, Tabatabai G, Sahm F, von Deimling A, Zadeh G, Aldape KD. DNA methylation profiling to predict recurrence risk in meningioma: development and validation of a nomogram to optimize clinical management. Neuro Oncol. 2019; 21(7):901–910. DOI: 10.1093/neuonc/noz061.
Review
For citations:
Dinikina Y.V., Belogurova M.B. Major features of the 2021 WHO Classification of Tumors of the Central Nervous System: clinician’s view. Russian Journal for Personalized Medicine. 2022;2(4):77-90. (In Russ.) https://doi.org/10.18705/2782-3806-2022-2-4-77-90
Views:
3931
Email this article 